Headquarters: Cambridge, United Kingdom
CEO: Dr. Tim J. Mitchell Ph.D.
GBP as of April 1, 2022
|Company||Market Cap (USD)|
|Novo Nordisk||$257.24 B|
|CSL Limited||$89.69 B|
|Regeneron Pharmaceuticals, Inc.||$74.91 B|
|Moderna, Inc.||$70.81 B|
|Vertex Pharmaceuticals Incorporated||$67.49 B|
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Sareum Holdings plc has the following listings and related stock indices.
Stock: LSE: SAR